Adult adherent stromal cells in the management of graft-versus-host disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2014-01-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.2014.866648PMID 24397853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human multipotent adult progenitor cells transcriptionally regulate fucosyltransferase VII.

  2014cited by this paper
• Clinical-Grade Multipotent Adult Progenitor Cells Durably Control Pathogenic T Cell Responses in Human Models of Transplantation and Autoimmunity

  2013cited by this paper
• Genetics of graft-versus-host disease: the major histocompatibility complex.

  2013cited by this paper
• Dissection of the Human Multipotent Adult Progenitor Cell (MAPC) Secretome by Proteomic Analysis

  2013cited by this paper
• Dissection of the Human Multipotent Adult Progenitor Cell Secretome by Proteomic Analysis

  2013cited by this paper
• Assessing response of therapy for acute and chronic graft-versus-host disease

  2013cited by this paper
• Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum

  2012cited by this paper
• Correction of Post-Transplant Hematopoiesis by Novel Use of Mesenchymal-Like Placental Expanded Cells (PLX) Administered Intra-Muscular

  2012cited by this paper
• Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease.

  2012cited by this paper
• Mesenchymal Stem Cells Inhibit Thymic Reconstitution After Allogeneic Cord Blood Transplantation

  2012cited by this paper
• What predicts high risk acute graft‐versus‐host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score

  2012cited by this paper
• Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.

  2012cited by this paper
• Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.

  2012cited by this paper
• Prophylaxis of Acute GVHD Using Multistem® Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses in a Phase 1 Trial

  2012cited by this paper
• Peak serum: implications of serum supply for cell therapy manufacturing.

  2012cited by this paper
• Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

  2011cited by this paper
• Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

  2011cited by this paper
• Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

  2011cited by this paper
• Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.

  2011cited by this paper
• Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.

  2011cited by this paper
• Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

  2011cited by this paper
• Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases

  2011cited by this paper
• Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD

  2010cited by this paper
• Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin

  2010cited by this paper
• Mesenchymal stem cell as salvage treatment for refractory chronic GVHD

  2010cited by this paper
• Altered Gene Expression in Human Adipose Stem Cells Cultured with Fetal Bovine Serum Compared to Human Supplements

  2010cited by this paper
• Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.

  2010cited by this paper
• Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report.

  2010cited by this paper
• Treatment Of Steroid-Refractory Acute GVHD With Mesenchymal Stem Cells Improves Outcomes In Pediatric Patients; Results Of The Pediatric Subset In A Phase III Randomized, Placebo-Controlled Study

  2010cited by this paper
• Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells.

  2009cited by this paper
• Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors

  2009cited by this paper
• Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.

  2009cited by this paper
• MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2.

  2009cited by this paper
• Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.

  2009cited by this paper
• Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

  2009cited by this paper
• A biomarker panel for acute graft-versus-host disease.

  2009cited by this paper
• Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow

  2009cited by this paper
• Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.

  2009cited by this paper
• Graft-versus-host disease.

  2009cited by this paper
• IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

  2008cited by this paper
• The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study

  2008cited by this paper
• HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

  2008cited by this paper
• Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

  2008cited by this paper
• Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

  2008cited by this paper
• Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

  2007cited by this paper
• Human AB Serum and Thrombin‐Activated Platelet‐Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue

  2007cited by this paper
• Graft-versus-host disease

  2007cited by this paper
• Human Heart, Spleen, and Perirenal Fat-Derived Mesenchymal Stem Cells Have Immunomodulatory Capacities

  2007cited by this paper
• An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.

  2006cited by this paper
• Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

  2006cited by this paper
• Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

  2006cited by this paper
• Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

  2006cited by this paper
• Human mesenchymal stem cells modulate B-cell functions.

  2006cited by this paper
• Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

  2006cited by this paper
• Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.

  2005cited by this paper
• Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.

  2005cited by this paper
• Mesenchymal stem cells avoid allogeneic rejection

  2005cited by this paper
• Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.

  2005cited by this paper
• Human mesenchymal stem cells modulate allogeneic immune cell responses.

  2005cited by this paper
• Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

  2005cited by this paper
• T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.

  2005cited by this paper
• Critical Parameters for the Isolation of Mesenchymal Stem Cells from Umbilical Cord Blood

  2004cited by this paper
• Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation.

  2004cited by this paper
• Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

  2004cited by this paper
• Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review.

  2003cited by this paper
• Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex

  2003cited by this paper
• Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft

  2003cited by this paper
• Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.

  2003cited by this paper
• Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential.

  2003cited by this paper
• Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

  2003cited by this paper
• W/Wv marrow stromal cells engraft and enhance early erythropoietic progenitors in unconditioned Sl/Sld murine recipients

  2002cited by this paper
• A survey of diagnosis, management, and grading of chronic GVHD.

  2002cited by this paper
• Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

  2002cited by this paper
• Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone

  2002cited by this paper
• Polycythemia vera: myths, mechanisms, and management.

  2002cited by this paper
• Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.

  2002cited by this paper
• Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow.

  2001cited by this paper
• Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow.

  2000cited by this paper
• Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.

  2000cited by this paper
• T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

  1998cited by this paper
• Phenotypic and functional comparison of cultures of marrow‐derived mesenchymal stem cells (MSCs) and stromal cells

  1998cited by this paper
• IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE

  1997influential reference
• Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

  1995cited by this paper
• Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.

  1995cited by this paper
• Bone marrow stromal function from patients after bone marrow transplantation.

  1995influential reference
• T-cell Depleted Bone Marrow Transplantation

  1995cited by this paper
• Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors.

  1994cited by this paper
• Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation.

  1993cited by this paper
• The role of conditioning regimens in homing of transplanted hemopoietic cells.

  1992influential reference
• BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis

  1991influential reference
• Molecular bases of dominant negative and loss of function mutations at the murine c‐kit/white spotting locus: W37, Wv, W41 and W.

  1990cited by this paper
• Comparative analysis of hematopoietic growth factors released by stromal cells from normal donors or transplanted patients.

  1990influential reference
• The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus.

  1990cited by this paper
• Long-term effects of cytostatic agents on the hemopoietic stroma: a comparison of four different assays.

  1987influential reference
• Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies.

  1984influential reference
• In vitro duplication and ‘cure’ of haemopoietic defects in genetically anaemic mice

  1977cited by this paper
• Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma.

  1977influential reference
• STROMAL CELLS RESPONSIBLE FOR TRANSFERRING THE MICROENVIRONMENT OF THE HEMOPOIETIC TISSUES: Cloning In Vitro and Retransplantation In Vivo

  1974cited by this paper

• Hematopoietic Stem Cells and Their Niche in Bone Marrow

  2024cites this paper
• Wharton’s jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications

  2023cites this paper
• An Update for Mesenchymal Stem Cell Therapy in Lupus Nephritis

  2021cites this paper
• Acute Graft-Versus-Host Disease (GvHD)

  2021cites this paper
• Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus

  2021cites this paper
• Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges

  2020cites this paper
• Cancer Stem Cells and their Management in Cancer Therapy.

  2020cites this paper
• Fibroblasts as a practical alternative to mesenchymal stem cells

  2018cites this paper
• Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy

  2017cites this paper
• Immunomodulatory mechanisms of mesenchymal stem cells and their therapeutic applications.

  2017cites this paper
• Mesenchymal Stromal Cells and the Approach to Clinical Trial Design: Lessons Learned From Graft Versus Host Disease

  2017cites this paper
• Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models

  2016cites this paper
• Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment

  2016cites this paper
• Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study

  2016cites this paper
• Mesenchymal stromal cells: potential roles in graft‐versus‐host disease prophylaxis and treatment

  2016influential citation
• Therapeutic Stem Cells Answer a Strategic Breakthrough Need of Healthcare

  2016cites this paper
• Title Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington ' s Disease Mouse Models

  2016cites this paper
• Stem Cells Targeting Inflammation as Potential Anti-aging Strategies and Therapies

  2015cites this paper
• The potential of mesenchymal stem cells in the management of radiation enteropathy

  2015cites this paper
• Mesenchymal stem cells transplantation for systemic lupus erythematosus

  2015cites this paper
• Transplantation of Bone Marrow Mesenchymal Stem Cells Promotes Learning and Memory Functional Recovery and Reduces Hippocampal Damage in Rats With Alcohol-Associated Dementia

  2015cites this paper
• Ex Vivo Induced Regulatory Human/Murine Mesenchymal Stem Cells as Immune Modulators

  2015cites this paper
• Tissue-Specific Progenitor and Stem Cells Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells

  2015cites this paper
• The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.

  2015cites this paper
• Acute graft-versus-host disease: a bench-to-bedside update.

  2014cites this paper
• ADVANCES IN HEMATOPOIETIC CELL TRANSPLANTATION Acute graft-versus-host disease: a bench-to-bedside update

  2014cites this paper
• Implication de l'axe CX3CL1/CX3CR1 dans la physiopathologie de la réaction aiguë du greffon contre l'hôte en allogreffe de cellules souches hématopoïétiques

  2014cites this paper